The intestinal microbiome is associated with clinical outcomes after anti-CD19 CAR T cell therapy in patients with B-cell malignancies.

This blog reflects on the journey that led to the publication of our preoperative combination immunotherapy study in Nature Medicine.

What value does deciphering the whole genome hold for guiding clinical care of children with high-risk cancer? Does it provide more accurate diagnoses, more treatment options, better risk stratification? Can it be analyzed fast enough to have real-time clinical impact?

In the November issue of Nature Medicine we describe the development of a first-in-class inhibitor of CLCF1 signaling and its effectiveness in several precllinical models of lung adenocarcinoma